金斯瑞生物科技(01548.HK)2024年財報:持續經營業務穩步增長,研發投入助力未來發展
格隆匯3月12日丨金斯瑞生物科技(01548.HK)發佈公吿,截至2024年12月31日止年度,集團收益持續增長。報吿期內集團持續經營業務的收益約為5.945億美元,較上期的約5.605億美元增加6.1%。報吿期內集團持續經營業務的毛利約為2.721億美元,較上期保持穩定。報吿期內集團的利潤約為29億美元,而上期集團的虧損約為3.551億美元,其中,持續經營業務的虧損約為1.738億美元,而上期的利潤約為1.629億美元;已終止經營業務的利潤約為30億美元,而上期的虧損約為5.18億美元。細胞療法業務解除合併收益約為32億美元,在報吿期內為集團帶來重大利潤增長。報吿期內集團持續經營業務的經調整淨利潤約為5980萬美元,較上期的約5810萬美元增加2.9%。
2024年,集團錄得收益約5.945億美元,較2023年的約5.605億美元增加6.1%。這主要是由於(i)持續投入商業推廣(尤其在歐洲和美國),業務品牌知名度增加;及(ii)推出新的競爭性服務和產品帶來市場份額增長。2024年,研發開支由2023年的約5270萬美元,增加2.1%至約5380萬美元。經調整研發開支較上期增加1.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.